Penn Capital Management Company, LLC Neurocrine Biosciences Inc Transaction History

Penn Capital Management Company, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $9,071 - $10,800	-85 Reduced 2.53%	3,271 $391,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $14,172 - $16,602	-154 Reduced 4.39%	3,356 $356,000
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $4,320 - $5,703	-57 Reduced 1.6%	3,510 $342,000
Q1 2022 May 17, 2022	BUY	$72.45 - $94.81 $50,062 - $65,513	691 Added 24.03%	3,567 $334,000
Q4 2021 Feb 17, 2022	BUY	$79.65 - $106.22 $796 - $1,062	10 Added 0.35%	2,876 $245,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $12,840 - $14,755	-149 Reduced 4.94%	2,866 $275,000
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $2,504 - $2,863	-28 Reduced 0.92%	3,015 $293,000
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $963 - $1,313	-11 Reduced 0.36%	3,043 $296,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.69 Million - $2.1 Million	-19,401 Reduced 86.4%	3,054 $293,000
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $775,241 - $1.09 Million	8,062 Added 56.01%	22,455 $2.22 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $1.22 Million - $1.88 Million	14,393 New	14,393 $1.8 Million

635

93.5M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Penn Capital Management Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Penn Capital Management Company, LLC with notifications on news.